Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.39 |
| ▸ | HTR3B | O95264 | 2/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17730315 | 1.00 | HTR3A (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL17730318 | 1.00 | HTR3A (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL19578989 | 1.00 | HTR3A (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL19629615 | 1.00 | HTR3A (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL17730316 | 1.00 | HTR3A (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL17730314 | 1.00 | HTR3A (0.39) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL19629616 | 0.96 | HTR3A (0.38) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL22472756 | 0.96 | HTR3A (0.38) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL25579932 | 0.95 | HTR3A (0.38) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL19629454 | 0.87 | CD38 (0.41) | KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-07-18 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | HTR3A 2088/4885HTR3E 3128/4885HTR3B 2337/4885 |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | HTR3A 1851/4885HTR3E 3035/4885HTR3B 2103/4885 |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | HTR3A 2288/4885HTR3E 3447/4885HTR3B 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.